Literature DB >> 2683028

Non-steroidal anti-inflammatory drug-induced disease in the distal ileum and large bowel.

L Aabakken1, M Osnes.   

Abstract

Non-steroid, anti-inflammatory drug (NSAID)-induced lesions in the gut are common, but so far most focus has been placed on the gastroduodenal mucosa. However, an increasing number of reports describe deleterious effects on the distal gut as well. Findings range from asymptomatic mucosal inflammation to stricture and obstruction, perforations, and major hemorrhages. Induction and exacerbation of inflammatory bowel disease has also been noted for most of the commercially available NSAIDs. Although final proof of a causal relationship is lacking, the indices present strongly suggest such a connection. The mechanism is largely unknown, although inhibition of cyclooxygenase with subsequent depletion of endogenous prostanoid synthesis has been suggested as a mediator. If surgery can be avoided, stopping the NSAID therapy is often sufficient to obtain lasting remission. The main point is knowledge of this facet of NSAID use, so that the pertinent drug history is obtained. Determination of the distal gut effects should probably also be included in the evaluation of present and future NSAIDs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2683028     DOI: 10.3109/00365528909091175

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  10 in total

1.  Non-steroidal anti-inflammatory drug-induced jejunal and colonic diaphragm disease: a report of two cases.

Authors:  I W Fellows; J M Clarke; P F Roberts
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

2.  Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs.

Authors:  E Sacanella; F Muñoz; F Cardellach; R Estruch; O Miró; A Urbano-Márquez
Journal:  Postgrad Med J       Date:  1996-01       Impact factor: 2.401

3.  Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism.

Authors:  A Z Leite; A M Sipahi; A O Damião; A M Coelho; A T Garcez; M C Machado; C A Buchpiguel; F P Lopasso; M L Lordello; C L Agostinho; A A Laudanna
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Focal reduction of villous blood flow in early indomethacin enteropathy: a dynamic vascular study in the rat.

Authors:  D A Kelly; C Piasecki; A Anthony; A P Dhillon; R E Pounder; A J Wakefield
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

5.  Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions.

Authors:  Manfred Stolte; Diana Karimi; Michael Vieth; Hildegard Volkholz; Klaus Dirschmid; Sigrid Rappel; Birgit Bethke
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

6.  Gastric Perforation as a Complication of COVID-19 Infection: A Case Report.

Authors:  Abdulrahman S Almulhim; Alaa Alghazzi; Ali A Almohammed Saleh; Ahmed H Alsulaiman; Lojain A Alnosair; Fatimah Y Alghareeb
Journal:  Cureus       Date:  2022-04-01

7.  Dependency of gastrointestinal toxicity on release rate of tiaprofenic acid: a novel pharmacokinetic-pharmacodynamic model.

Authors:  M Vakily; F Khorasheh; F Jamali
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

8.  Neutropenia does not prevent etodolac- or indomethacin-induced gastrointestinal damage in the rat.

Authors:  R Melarange; C Gentry; C D Toseland; P H Smith; J Fuller
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

9.  Childhood infections and the risk of inflammatory bowel disease.

Authors:  J I Wurzelmann; C M Lyles; R S Sandler
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

Review 10.  Gut Microbiota in NSAID Enteropathy: New Insights From Inside.

Authors:  Xianglu Wang; Qiang Tang; Huiqin Hou; Wanru Zhang; Mengfan Li; Danfeng Chen; Yu Gu; Bangmao Wang; Jingli Hou; Yangping Liu; Hailong Cao
Journal:  Front Cell Infect Microbiol       Date:  2021-07-06       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.